Lyka Labs Limited (IN:LYKALABS)
:LYKALABS
Want to see IN:LYKALABS full AI Analyst Report?
LYKALABS Stock Chart & Stats
₹94.40
-₹1.55(-0.97%)
At close: 4:00 PM EST
₹94.40
-₹1.55(-0.97%)
Day’s Range― - ―
52-Week Range₹44.49 - ₹121.00
Previous CloseN/A
Volume78.41K
Average Volume (3M)3.02K
Market Cap
₹2.51B
Enterprise Value₹2.99B
Total Cash (Recent Filing)₹11.89M
Total Debt (Recent Filing)₹316.57M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.55
Shares Outstanding35,690,000
10 Day Avg. Volume1,252
30 Day Avg. Volume3,017
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.74
Price to Sales (P/S)1.25
P/FCF Ratio-21.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving LeverageMaterial reduction in reported debt over three years meaningfully lowers leverage and refinancing risk. A stronger balance sheet increases strategic optionality for capex, regulatory compliance and partnerships, improving long-term resilience versus prior high-leverage years.
Diversified Pharma Manufacturing ModelOperating across APIs and finished formulations and selling to B2B, institutional and export channels provides multiple revenue streams. This structural diversification supports stability versus single-product firms and enables scaling via contract manufacturing and export growth over months to years.
Positive Operating Cash FlowSustained positive operating cash generation even during an accounting loss implies core operations convert sales into cash. That cash buffers working capital needs, supports incremental investments and reduces immediate reliance on external financing, a durable sign of operational cash health.
Bears Say
Revenue Decline And Net LossA year-over-year revenue drop combined with a sharp swing to a substantial net loss signals demand, pricing or execution issues. Persistent top-line weakness and earnings reversals undermine reinvestment, debt repayment capacity and long-term margin sustainability if not reversed.
Consistently Negative Free Cash FlowProlonged negative free cash flow forces dependence on external financing or asset sales to fund capex and operations. Over months this limits ability to deleverage, invest in capacity or navigate regulatory inspections, raising execution and liquidity risk despite positive operating cash.
Volatile Earnings QualityRepeated swings between profit and loss point to inconsistent cost control, product mix or execution. This volatility reduces forecasting reliability, increases the probability of future losses and complicates long-term planning for margin improvement and sustainable growth.
Lyka Labs Limited News
LYKALABS FAQ
What was Lyka Labs Limited’s price range in the past 12 months?
Lyka Labs Limited lowest stock price was ₹44.49 and its highest was ₹121.00 in the past 12 months.
What is Lyka Labs Limited’s market cap?
Lyka Labs Limited’s market cap is ₹2.51B.
When is Lyka Labs Limited’s upcoming earnings report date?
Lyka Labs Limited’s upcoming earnings report date is Aug 07, 2026 which is in 48 days.
How were Lyka Labs Limited’s earnings last quarter?
Lyka Labs Limited released its earnings results on May 25, 2026. The company reported -₹2.13 earnings per share for the quarter, missing the consensus estimate of N/A by -₹2.13.
Is Lyka Labs Limited overvalued?
According to Wall Street analysts Lyka Labs Limited’s price is currently Overvalued.
Does Lyka Labs Limited pay dividends?
Lyka Labs Limited does not currently pay dividends.
What is Lyka Labs Limited’s EPS estimate?
Lyka Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lyka Labs Limited have?
Lyka Labs Limited has 35,690,000 shares outstanding.
What happened to Lyka Labs Limited’s price movement after its last earnings report?
Lyka Labs Limited reported an EPS of -₹2.13 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.162%.
Which hedge fund is a major shareholder of Lyka Labs Limited?
Currently, no hedge funds are holding shares in IN:LYKALABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lyka Labs Limited
Established in 1976 and headquartered in Mumbai, India, Lyka Labs Limited is a pharmaceutical firm specializing in the development, manufacturing, and marketing of a wide array of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses numerous therapeutic areas, including intensive care, gastroenterology, anti-infectives, anti-fungals, surgery, urology, wound care, anesthesia, and various dermatological and cosmeceutical applications like topical steroids, anti-acne, anti-aging, and hair care. These products are available in diverse forms, such as injections, creams, ointments, gels, and lotions. Beyond its own offerings, Lyka Labs also provides contract manufacturing services to other major pharmaceutical companies and offers comprehensive medical and technical support. This support includes manufacturing expertise, facility assistance, and crucial technical data such as molecule stability testing, impurity profiling, and bioequivalence (BA/BE) clinical study data. The company's market reach extends globally, with exports to various countries including Bangladesh, Cambodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
SMS Lifesciences India Ltd.
―
Supriya Lifescience Limited
―
Zota Health Care Ltd.
―